IAG Monthly Newsletter |🔎Smarter Oncology Trials with AI & Imaging
Editorial Introduction
February 27, 2026
February has been a dynamic month for IAG and our partners. The spotlight was firmly on oncology, from insightful conversations at the SCOPE Summit and Immuno-Oncology 360 (IO360), to our live webinar on 19 February on Practical Guide to Smarter Oncology Trials: DYNAMIKA™, RECIST, Volumetrics, Radiomics and AI.
Across these engagements, one theme resonated: imaging and AI are no longer adjuncts in oncology drug development – they are central to smarter, faster trials.
Indication in the Spotlight: Oncology
Oncology continues to lead in innovation and investment, with imaging-derived endpoints gaining regulatory traction as objective measures of response.
At IAG, we see Sponsors increasingly integrating quantitative MRI, radiomics, and AI-assisted response evaluation to strengthen early efficacy signals. Equally, centralized imaging management is becoming vital to ensure consistency across global Phase II–III trials.
Our scientific and operational teams are supporting oncology developers through data-driven imaging strategies that align with evolving FDA and EMA guidance helping sponsors make faster, evidence-based go/no-go decisions.
Market Trends & Insights
- Oncology accounted for over 40% of all Phase I–III trials initiated in early 2026, with imaging cited as a key efficacy or safety endpoint.
- Biotechs, especially those who are reliant on AI or more advanced drug discovery mechanisms and more technology savvy, are increasingly seeking strategic CRO partnerships for centralized imaging management and data standardization.
- AI-enabled image analysis and radiomic feature extraction are gaining acceptance for exploratory endpoints in early trials and translational research.
These shifts confirm that the intersection of AI and imaging is redefining oncology development practices.
Thus, platforms like DYNAMIKA™ become essential to oncology drug developers.
Inside IAG: Innovation in Action
Our platform, DYNAMIKA™, continues to be the backbone of multi-center oncology trials, ensuring standardized image acquisition, automated QC conducted within less than a day, and reliable quantitative endpoints to supplement RECIST 1.1/ iRECIST for successful delivery.
This month, our team demonstrated how automated workflows reduce site burden and improve image read quality, enabling real-time decision-making for Sponsors. By combining expertise in imaging biomarker science and intelligent technology, we’re helping oncology programs transition from qualitative reads to data-driven insights which is critical in modern day clinical trials.
👉 Discover more: https://www.ia-grp.com/dynamika/
Collaboration & Event Highlights
At SCOPE Summit, IO360 Conference, & GBM Summit, IAG engaged with C-Level executives, operational leaders, and biomarker scientists to discuss how imaging data can accelerate study design and early efficacy assessment.
Conversations centered on topics such as using imaging to stratify patients in oncology trials, reader discrepancy control, and of-course reduction of operational costs.
Image Analysis Group (IAG) – SCOPE Summit 2026
These discussions highlighted IAG’s collaborative approach, working hand-in-hand with Sponsors to make imaging a powerful decision-support tool across multiple indications.
Webinar Recap: Practical Guide to Smarter Oncology Trials
On 19 February, we hosted a lively session “A Practical Guide to Smarter Oncology Trials: DYNAMIKA™” where our experts demonstrated how centralized imaging and AI analytics improve data quality and trial efficiency.
Key Takeaways Included:
- How automated workflows improve site performance and reduce delays.
- How central review by AI and expert oversight enhances consistency and reproducibility.
- How radiomics can enrich oncology endpoints and accelerate translational insights.
A discussion with Trishan Arul, CEO of Picture Health, provided an additional perspective on leveraging AI for more confident decision-making in oncology trials.
▶ Missed us? Request the recording by emailing: contact@ia-grp.com
Coming Up Next
Conferences:
Join IAG at the following upcoming oncology and imaging meetings:
- American Academy of Orthopaedic Surgeons (AAOS) – 03/03/2026 – New Orleans, USA
- Targeted Anticancer Therapies Congress (ESMO) – 03/16/2026 – Paris, France
- 6th Global Conference on Myositis (GCOM) – 03/23/2026 – Lisbon, Portugal
- Special Conference in Cancer Research (AACR) – 03/23/2026 – Philadelphia, Pennsylvania
- Creating Value in Changing Times (HBI) – 03/23/2026 – Paris, France
- European Lung Cancer Congress (ELCC) – 03/25/2026 – Copenhagen, Denmark
We will be available for 1:1 discussions on imaging strategy, endpoint design, and the use of DYNAMIKA™ in early‑ and late‑phase trials.
Practical Guide to Clinical Trial Imaging in Autoimmune Diseases: DYNAMIKA™, AI, and Endpoint Strategies
📅 Thursday, 19 March 2026 | 12:00 PM – 1:00 PM EDT
Join IAG and our experts for a deep dive into imaging biomarkers and endpoint design in myositis, scleroderma, and inflammatory arthritis.
Speakers: Dr. Olga Kubassova, Jonathan Himoff, Cristiano Costa, Mikael Boesen
Key Areas of Discussion Include:
- Imaging as a decision-making tool in autoimmune and rheumatic disease trials.
- Designing and standardizing imaging protocols in multicenter autoimmune studies.
- Quantitative imaging and endpoint selection for immunotherapy trials.
- Expert insights, platform-enabled workflows, and live Q&A.
Explore how DYNAMIKA™ supports data standardization and endpoint validation in autoimmune trials and how imaging can accelerate drug development for novel and advanced immunotherapies.
👉 Read the full agenda and register your attendance here: https://events.teams.microsoft.com/event/38826722-4d4b-449f-b79b-9d35a979ac3e@9d8bbb25-87cf-4b56-9b33-dfac006f6cf6
Featured Insight
AI‑Powered Oncology Imaging in Early‑Phase Trials
IAG is using lesion‑ and tumor‑focused AI within DYNAMIKA™ to generate faster, regulator‑ready imaging endpoints for complex solid‑tumor studies and to support sharper early go/no‑go decisions in oncology development.
Read now → https://www.ia-grp.com/early-phase-clinical-trials-clinical-trial-imaging/
Organizational Growth
Derek Hunter – Head of Quality / Jonathan Shaul – Chief Financial Officer
Image Analysis Group (IAG) has expanded its leadership team with two strategic appointments that reinforce our focus on excellence in clinical trial delivery and sustainable growth. Derek Hunter has joined as Head of Quality, and Jonathan Shaul has been appointed Chief Financial Officer (CFO).
Derek Hunter, Head of Quality (as seen above):
Derek brings over 20 years of experience in quality management across the life sciences and biotech sectors. At IAG, he will oversee our quality systems, ensuring that clinical trial operations, data integrity, and client delivery continue to meet the highest regulatory and industry standards. As Derek notes, “IAG has built a reputation for precision and reliability in clinical trial imaging. I’m excited to help strengthen these systems and ensure that every solution meets the rigorous standards our clients expect.”
Jonathan Shaul, Chief Financial Officer (as seen above):
Jonathan is a seasoned finance executive with a track record of scaling high‑growth life sciences companies. He will lead IAG’s financial strategy with a focus on operational efficiency, financial planning, and strategic growth initiatives. “Joining IAG at this stage of its growth is a tremendous opportunity,” Jonathan comments. “I look forward to supporting the company as it expands its global footprint and continues to deliver innovative, data‑driven solutions to its clients.”
As Dr. Olga Kubassova, CEO of IAG, noted, these appointments reflect our ongoing commitment to excellence, compliance, and sustainable growth as we continue to support biotech and pharma partners with innovative, data‑driven solutions for complex clinical trials.
👉 Read more: https://www.ia-grp.com/news/executive-leadership-expansion/
Closing Note
As oncology imaging moves firmly into the era of AI and quantitative endpoints, IAG remains focused on enabling data-backed decisions that make clinical trials faster, more reliable, and scientifically sound.
Contact
🌐Visit our website: www.ia-grp.com
✅ Follow IAG on LinkedIn for monthly insights, and get in touch if you’d like to explore how we can strengthen your imaging strategy.
📅 Book a short strategy call with our imaging experts to pressure‑test your current oncology trial design: contact@ia-grp.com
About Image Analysis Group (IAG)
Image Analysis Group (IAG) is a science‑driven imaging CRO specializing in advanced imaging strategies and quantitative biomarkers for clinical trials. The company partners with biotech, pharmaceutical, and medical device organizations to design and deliver imaging‑enabled studies across oncology, neuro‑oncology, rheumatology, radiopharma, immunology, and metabolic diseases, providing robust data to support faster, more informed R&D decisions.
For nearly 20 years, IAG has supported more than 700 clinical trials globally, helping biotech and pharmaceutical sponsors make confident, data‑driven decisions on their development portfolios.
Discover how DYNAMIKA™ helps sponsors manage complex datasets, harmonize imaging and endpoint data, and enable real-time insights across neuro-oncology trials.
Book a DYNAMIKA™ demo today to explore how an intelligent clinical data platform can streamline operations, improve decision-making, and accelerate your next trial.
